A Republican bill with 1 Democratic cosponsor · See all 2 cosponsors
Last activity — Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
This bill, known as the "CLEAR LABELS Act," seeks to amend the Federal Food, Drug, and Cosmetic Act. It would require drug labeling to include specific information regarding the original manufacturer and the supply chain. For finished drug products, the label must identify the original manufacturer of each active pharmaceutical ingredient, the original manufacturer of the finished product, and any packer or distributor. The bill also requires that this information be accessible via links, barcodes, or QR codes. Additionally, the Act amends the Tariff Act of 1930 regarding certain marking requirements.
Yes· 3 of 5
- Scored +5
Does this give people more protection from unfair business practices?
The bill increases consumer protection by requiring transparent labeling of the drug supply chain and original manufacturers.
- Scored +4
Does this make what the government does easier for the public to see?
The bill increases transparency in the pharmaceutical supply chain by mandating the disclosure of manufacturer and distributor identities.
- Scored +2
Does this make health care easier to get in general?
The bill improves information access for healthcare consumers through electronic portals and physical documentation of drug origins.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Increased Transparency of the Drug Supply Chain: Under Section 2, drug labeling would be required to include the name, place of business, and unique facility identifier of the original manufacturer of active pharmaceutical ingredients, the finished drug product, and any packer or distributor. This provides more detailed information about where drugs come from.
-
Improved Access to Information: Section 2 allows for the use of a link, barcode, QR code, or other means to access a searchable electronic portal containing manufacturer information, making it easier for people to find necessary details.
-
Availability of Physical Documentation: Section 2(4) requires that manufacturers, packers, or distributors make the required information available through a package insert or in a paper copy to any individual who requests it.
Potential Negative Impacts for People
- No specific negative impacts are explicitly listed in the provided text.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Economy And Finance
- Does this give people more protection from unfair business practices? — The bill increases consumer protection by requiring transparent labeling of the drug supply chain and original manufacturers.
- Governance And Ideology
- Does this make what the government does easier for the public to see? — The bill increases transparency in the pharmaceutical supply chain by mandating the disclosure of manufacturer and distributor identities.
- Demographic And Interest Groups
- Would households on low incomes be better off under this? — Providing physical copies of manufacturing information ensures that people without digital access can still obtain supply chain transparency. Would people in cities be better off under this? — The requirement to provide paper copies of information can benefit all residents, including those in urban areas with varying levels of digital access.
- Healthcare
- Does this make health care easier to get in general? — The bill improves information access for healthcare consumers through electronic portals and physical documentation of drug origins.
- 6/3/2026
- 1 Cosponsor added.
- 4/14/2026
- Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 1 Cosponsor added.
- Introduced in House
One bill Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.
Rosa DeLauroDemocrat · Connecticut
Clay FullerRepublican · Georgia